Alzheimers Drug-Development Program (U01 Clinical Trial Optional)
Forecasted
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
Funder: National Institutes of Health
Due Dates (Anticipated): June 2027 (Full application deadline, projected)
Funding Amounts: Award amounts not yet specified; cooperative agreement (U01); multi-year support expected.
Summary: Supports pre-clinical and early-stage clinical (Phase I) development of novel drug candidates to prevent, slow, or treat Alzheimer’s disease.
Key Information: This is a forecasted opportunity; application details and amounts will be confirmed when the NOFO is published.
Description
The National Institute on Aging (NIA) plans to continue the Alzheimer's Drug-Development Program (ADDP) to support the pre-clinical and early-stage clinical (Phase I) development of innovative small-molecule and biologic drug candidates for Alzheimer’s disease (AD). The program aims to catalyze drug development by funding the most challenging and expensive steps, bridging preclinical research and first-in-human testing. Projects may target prevention, slowing of disease progression, or treatment of cognitive and behavioral symptoms. The program encourages applications that expand the portfolio of investigational drug candidates, address multiple disease mechanisms, and enable precision medicine approaches for AD.
